0000883984-20-000021 | 10-Q | XBRL Viewer

Lessee, Operating Leases [Text Block]

Leases

We determine if an arrangement is a lease at inception. Our operating lease assets are separately stated in operating lease right-of-use ("ROU") assets and our financing lease assets are included in other assets on our condensed consolidated balance sheets. Our lease liabilities are included in accrued liabilities, and other long-term liabilities on our condensed consolidated balance sheets. We have elected not to recognize an ROU asset and lease liability for leases with terms of twelve months or less.

Lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Most of our leases do not provide an implicit rate, therefore we use our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term based on the information available at commencement date. Our lease ROU assets exclude lease incentives and initial direct costs incurred. Our lease terms include options to extend when it is reasonably certain that we will exercise that option. All of our operating leases have stated lease payments, which may include fixed rental increases. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

Our leases are for corporate offices, sales and support offices, a distribution facility, device service centers and certain equipment. Our leases have original lease terms of one year to fifteen years, some of which include options to extend the leases for up to an additional five years. For all of our leases, we do not include optional periods of extension in our current lease terms for the exercise of options to extend is not reasonably certain.

The following table presents the components of our lease cost (in thousands):



	For the three months ended March 31,
	2020		2019
Operating lease cost	$	2,791	$	2,430

Finance lease cost	29		—

Short-term lease cost	54		96

Total lease cost	$	2,874	$	2,526

The following table presents the supplemental cash flow information related to our leases (in thousands):



	For the three months ended March 31,
	2020		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	2,457	$	2,219
Operating cash flows from finance leases	$	29	$	—

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	19,094	$	98
Finance leases	$	800	$	—

The following table presents the supplemental balance sheet information related to our operating leases (in thousands, except lease term and discount rate):



	As of March 31, 2020			As of December 31, 2019
Operating leases
Operating lease right-of-use assets	$	50,430		$	34,465

Accrued liabilities	$	7,544		$	7,362
Other long-term liabilities	45,166			28,896
Total operating lease liabilities	$	52,710		$	36,258

Weighted Average Remaining Lease Term
Operating leases	7.3 years			6.0 years

Weighted Average Discount Rate
Operating leases	5.06		%	5.57		%

The following table presents the supplemental balance sheet information related to our finance leases (in thousands, except lease term and discount rate):



	As of March 31, 2020
Financing leases
Financing lease right-of-use assets	$	789

Accrued liabilities	$	188
Other long-term liabilities	601
Total financing lease liabilities	$	789

Weighted Average Remaining Lease Term
Financing leases	4.0 years

Weighted Average Discount Rate
Financing leases	4.32		%

As of March 31, 2020, the maturities of our operating and financing lease liabilities for each of the next five years is approximately (in thousands):



	Operating Leases			Finance Leases
Remainder of 2020	$	7,195		$	174
2021	10,021			218
2022	9,309			218
2023	8,494			218
2024	8,094			25
2025	4,816			—
Thereafter	14,906			—
Total Lease Payments	62,835			853
Less imputed interest	(10,125		)	(64		)
Total	$	52,710		$	789

Net Income Per Share:

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Net Income Per Share [Text Block]

Net Income Per Share

Basic earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period plus dilutive securities. Dilutive securities include outstanding common stock options and unvested restricted stock units, less the number of shares that could have been purchased with the proceeds from the exercise of the options, using the treasury stock method. Options and restricted stock units that are anti-dilutive are not included in the treasury stock method calculation. There were 15,333 and 9,998 anti-dilutive securities for the three months ended March 31, 2020 and 2019, respectively.

The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands, except per share data):



	Three months ended March 31,
	2020		2019
Net income	$	16,834	$	30,998
Weighted-average number of common shares outstanding (for basic calculation)	20,780		20,527
Dilutive securities	727		1,024
Weighted-average common and common equivalent shares outstanding (for diluted calculation)	21,507		21,551
EPS — basic	$	0.81	$	1.51
EPS — diluted	$	0.78	$	1.44

Derivative Financial Instruments (Notes)

3 Months Ended

Mar. 31, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

Derivatives and Hedging Activities

Hedge Accounting and Hedging Program

The purpose of our hedging program is to manage the foreign currency exchange rate risk on forecasted expenses denominated in currencies other than the functional currency of the operating unit. We do not issue derivatives for trading or speculative purposes.

To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The par forward contract is designated and qualifies as a cash flow hedge. Our derivative instruments are recorded at fair value on the condensed consolidated balance sheets and are classified based on the instrument's maturity date. We record changes in the intrinsic value of the effective portion of the gain or loss on the derivative instrument as a component of Other Comprehensive Income and we reclassify that gain or loss into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.

In March 2020, we entered into a one-year cross-currency par forward contract that extends our current hedge of a portion of our Mexico forecasted expenses denominated in Pesos ("MXN"). The total notional amount of this outstanding derivative as of March 31, 2020 was approximately 473.2 million MXN. The term of the one-year contract is November 3, 2020 to December 1, 2021. The derivative instrument matures in equal monthly amounts at a fixed forward rate of 24.26 MXN/USD.

In November 2018, we entered into a one-year cross-currency par forward contract that hedges of a portion of our Mexico forecasted expenses denominated in MXN. The total notional amount of this outstanding derivative as of March 31, 2020 was approximately 265.3 million MXN. The term of the one-year hedge is November 1, 2019 to November 3, 2020. The derivative instrument matures in equal monthly amounts at a fixed forward rate of 22.109 MXN/USD.

The following table presents the fair values of our derivative instruments included within the Condensed Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019 (in thousands):



	Derivatives
	Condensed Consolidated Balance Sheet Location	March 31, 2020			December 31, 2019
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contract:
	Prepaid expenses and other current assets	$	—		$	2,366
	Accrued liabilities	(1,006		)	—
	Other long-term liabilities	(512		)	—
Total derivatives designated as cash flow hedging instruments		$	(1,518	)	$	2,366

The following table presents the amounts affecting the Condensed Consolidated Statements of Operations for the three months ended March 31, 2020 and 2019 (in thousands):



	Line Item in the Condensed Consolidated Statements of Operations	Three months ended March 31,
		2020		2019
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contracts	Cost of goods sold	$	692	$	155

We recognized the following (losses) gains on our foreign exchange contracts designated as a cash flow hedge (in thousands):



	Amount of (Loss) Gain Recognized in Other Comprehensive Income on Derivatives					Amount of Gain Reclassified From Accumulated Other Comprehensive Income into Income
	Three months ended March 31,						Three months ended March 31,
	Three months ended March 31,						Three months ended March 31,
	2020			2019		Location of Gain Reclassified From Accumulated Other Comprehensive Income into Income	2020		2019
Derivatives designated as cash flow hedges:
Foreign exchange forward contract	$	(3,192	)	$	1,010	Cost of goods sold	$	692	$	155
Total derivatives designated as cash flow hedging instruments	$	(3,192	)	$	1,010		$	692	$	155

As of March 31, 2020, we expect approximately $1.0 million of the deferred losses on the outstanding derivatives in accumulated other comprehensive income to be reclassified to net income during the next twelve months concurrent with the underlying hedged transactions also being reported in net income.

Fair Value Measurement:

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

Fair Value Measurement

Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There are three levels of inputs that may be used to measure fair value:


•	Level 1: quoted prices in active markets for identical assets or liabilities;

•

Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or


•	Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair values of the assets or liabilities.

Earn-out Liability

In 2017, we recognized an earn-out liability upon the acquisition of HIS from Pfizer. Pfizer was entitled up to $225 million in cash if certain performance targets for the combined company for the three years ending December 31, 2019 were achieved. The initial fair value of the earn-out was determined by employing a Monte Carlo simulation in a risk neutral framework. The underlying simulated variable was adjusted EBITDA. The adjusted EBITDA volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model included other assumptions including the market price of risk, which was calculated as the weighted average cost of capital ("WACC") less the long term risk free rate. The initial value assigned to the contingent consideration was a result of forecasted product demand of our HIS business. At each reporting date subsequent to the acquisition we remeasured the earn-out using the same methodology above and recognized any changes in value. As of December 31, 2019, it was determined that we did not meet the necessary performance targets that would require payout of any of the HIS earn-out liability.

In the fourth quarter of 2019, we recognized an earn-out liability related to the acquisition of Pursuit Vascular, Inc. ("Pursuit"). Pursuit's former equity holders are potentially entitled up to $50.0 million in additional cash consideration contingent upon the achievement of certain sales and gross profit targets for specific customers. The earn-out paid will be calculated as a percentage of gross profit achieved during the earn-out period against a pre-determined target gross profit, not to exceed $50.0 million. We used a Monte Carlo simulation model to determine the fair value of the earn-out liability. The Monte Carlo simulation model utilizes multiple input variables to determine the value of the earn-out liability including historical volatility, a risk free interest rate, counter party credit risk and projected future gross profit, see below simulation input table related to Pursuit. The historical volatility was based on the median of ICU and a certain peer group. The risk-free interest rate is equal to the yield, as of the valuation date, of the zero-coupon U.S. Treasury bill that is commensurate with the term of the earn-out. The counter party credit risk is based on a synthetic credit rating of B1. If the probabilities in the model significantly change from what we initially and subsequently anticipate, the change could have a significant impact on our financial statements in the period recognized. Our contingent earn-out liability is separately stated in our condensed consolidated balance sheets.

The following tables provide a reconciliation of the Level 3 earn-out liabilities measured at estimated fair value (in thousands):



	Pursuit
	Earn-out Liability
Accrued balance, January 1, 2020	$	17,300
Change in fair value of earn-out (included in income from operations as a separate line item)	—
Accrued balance, March 31, 2020	$	17,300



	HIS
	Earn-out Liability
Accrued balance, January 1, 2019	$	47,400
Change in fair value of earn-out (included in income from operations as a separate line item)	(7,700		)
Accrued balance, March 31, 2019	$	39,700

The fair value of the earn-out was the same at March 31, 2020 as the fair value calculated at December 31, 2019 as the underlying target forecast did not change.

The following tables provide quantitative information about Level 3 inputs for fair value measurement of our earn-out liabilities:

Pursuit Earn-out



Simulation Input	As of March 31, 2020		At Acquisition November 2, 2019
Revenue/Gross Profit Volatility	20.00	%	20.00	%
Discount Rate	15.00	%	15.00	%
Risk Free Rate	1.55	%	1.55	%
Counter Party Risk	6.00	%	6.00	%

HIS Earn-out



Simulation Input	As of March 31, 2019		As of December 31, 2018
Adjusted EBITDA Volatility	30.00	%	30.00	%
WACC	8.25	%	8.25	%
20-year risk free rate	2.63	%	2.87	%
Market price of risk	5.47	%	5.24	%
Cost of debt	4.35	%	5.25	%

Investments and Foreign Currency Contracts

The fair value of our investments is estimated using observable market-based inputs such as quoted prices, interest rates and yield curves or Level 2 inputs, which consisted of corporate bonds.

The fair value of our Level 2 forward currency contracts are estimated using observable market inputs such as known notional value amounts, spot and forward exchange rates. These inputs relate to liquid, heavily traded currencies with active markets which are available for the full term of the derivative.

Our assets and liabilities measured at fair value on a recurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):



	Fair value measurements at March 31, 2020
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Available for sale securities:
Short-term	$	20,115	$	—	$	20,115	$	—
Total Assets	$	20,115	$	—	$	20,115	$	—

Liabilities:
Earn-out liability	$	17,300	$	—	$	—	$	17,300
Foreign exchange forwards:
Accrued liabilities	1,006		—		1,006		—
Other long-term liabilities	512		—		512		—
Total Liabilities	$	18,818	$	—	$	1,518	$	17,300



	Fair value measurements at December 31, 2019
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Available for sale securities:
Short-term	$	23,967	$	—	$	23,967	$	—
Foreign exchange forwards:
Prepaid expenses and other current assets	2,366		—		2,366		—
Total Assets	$	26,333	$	—	$	26,333	$	—

Liabilities:
Earn-out liability	$	17,300	$	—	$	—	$	17,300
Total Liabilities	$	17,300	$	—	$	—	$	17,300

Investments, Debt and Equity Securities [Abstract]

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Investment Securities (Notes)

3 Months Ended

Mar. 31, 2020

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

Investment Securities

Our investment securities currently consist of short-term corporate bonds. Our investment securities are considered available-for-sale and are “investment grade” and carried at fair value. Available-for-sale securities are recorded at fair value, and unrealized holding gains and losses are recorded, net of tax, as a component of accumulated other comprehensive income. Unrealized losses on available-for-sale securities are charged against net earnings when a decline in fair value is determined to be other than temporary. Our management reviews several factors to determine whether a loss is other than temporary, such as the length and extent of the fair value decline, the financial condition and near term prospects of the issuer, and for equity investments, our intent and ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. The amortized cost of the debt securities are adjusted for the amortization of premiums computed under the effective interest method. Such amortization is included in investment income in other income on our condensed consolidated statements of operations. There have been no realized gains or losses on their disposal. Realized gains and losses are accounted for on the specific identification method. The scheduled maturities of the debt securities are between 2020 and 2021. All short-term investment securities are callable within one year.

Our short investment securities consisted of the following (in thousands):



	As of March 31, 2020
	Amortized Cost		Unrealized Holding Gains (Losses)		Fair Value
Short-term corporate bonds	$	20,115	$	—	$	20,115

	As of December 31, 2019
	Amortized Cost		Unrealized Holding Gains (Losses)		Fair Value
Short-term corporate bonds	$	23,967	$	—	$	23,967

Prepaids and Other Current Assets (Notes)

3 Months Ended

Mar. 31, 2020

Prepaid Expense and Other Assets, Current [Abstract]

Other Current Assets [Text Block]

Prepaid Expenses, Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):



	March 31, 2020		December 31, 2019
Other prepaid expenses and receivables	15,407		13,778
Deferred costs	6,493		3,332
Prepaid insurance and property taxes	4,548		5,450
VAT/GST receivable	3,913		4,422
Deferred tax charge	1,266		1,266
Deposits	1,316		1,375
Other	1,658		4,358
	$	34,601	$	33,981

Inventories:

3 Months Ended

Mar. 31, 2020

Inventory Disclosure [Abstract]

Inventories [Text Block]

Inventories

Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method. Inventory costs consist of those costs directly attributable to products prior to sale including among other things raw material, labor and overhead. Inventories consisted of the following (in thousands):



	March 31, 2020		December 31, 2019
Raw materials	$	121,674	$	119,709
Work in process	36,291		39,515
Finished goods	153,639		178,416
Total inventories	$	311,604	$	337,640

Property and Equipment:

3 Months Ended

Mar. 31, 2020

Property, Plant and Equipment [Abstract]

Property and Equipment [Text Block]

Property and Equipment

Property and equipment consisted of the following (in thousands):



	March 31, 2020			December 31, 2019
Machinery and equipment	$	241,059		$	219,057
Land, building and building improvements	233,548			230,454
Molds	60,312			60,155
Computer equipment and software	93,475			83,217
Furniture and fixtures	7,416			7,498
Instruments placed with customers⁽¹⁾	74,292			74,434
Construction in progress	77,483			101,425
Total property and equipment, cost	787,585			776,240
Accumulated depreciation	(331,961		)	(320,155		)
Property and equipment, net	$	455,624		$	456,085

______________________________

⁽¹⁾Instruments placed with customers consist of drug-delivery and monitoring systems placed with customers.

Depreciation expense was $15.2 million and $15.1 million for the three months ended March 31, 2020 and 2019, respectively.

Goodwill and Intangible Assets (Notes)

3 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

Goodwill and Intangible Assets, Net

Goodwill

The following table presents the changes in the carrying amount of our goodwill (in thousands):



	Total
Balance as of January 1, 2020	$	31,245
Currency translation	(478		)
Balance as of March 31, 2020	$	30,767

Intangible Assets, Net

Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):



	Weighted Average	March 31, 2020
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	22,854	$	13,886	$	8,968
Customer contracts	12	10,093		5,584		4,509
Non-contractual customer relationships	9	56,258		21,102		35,156
Trademarks	4	425		425		—
Trade name	15	18,237		2,555		15,682
Developed technology	13	152,893		27,403		125,490
Non-compete	3	2,500		347		2,153
Total amortized intangible assets		$	263,260	$	71,302	$	191,958

Internally developed software*		$	14,879			$	14,879

Total intangible assets		$	278,139	$	71,302	$	206,837

______________________________

* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.



	Weighted Average	December 31, 2019
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	22,322	$	13,519	$	8,803
Customer contracts	12	10,122		5,506		4,616
Non-contractual customer relationships	9	57,296		19,787		37,509
Trademarks	4	425		425		—
Trade name	15	18,256		2,254		16,002
Developed technology	13	152,354		24,228		128,126
Non-compete	3	2,500		139		2,361

Total amortized intangible assets		$	263,275	$	65,858	$	197,417

Internally developed software*		$	13,991			$	13,991

Total intangible assets		$	277,266	$	65,858	$	211,408

______________________________

* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.

Intangible assets with definite lives are amortized on a straight-line basis over their estimated useful lives. During the three months ended March 31, 2020 and 2019, intangible asset amortization expense was $5.8 million and $4.0 million, respectively.

As of March 31, 2020 estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands):



Remainder of 2020	$	17,424
2021	22,997
2022	22,355
2023	21,512
2024	21,422
2025	15,629
Thereafter	70,619
Total	$	191,958

Accrued Liabilities (Notes)

3 Months Ended

Mar. 31, 2020

Accrued Liabilities [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Accrued Liabilities and Other Long-Term Liabilities

Accrued liabilities consist of the following (in thousands):



	March 31, 2020		December 31, 2019
Salaries and benefits	$	27,616	$	21,116
Incentive compensation	8,638		15,221
Accrued supply chain restructuring costs	22,998		23,119
Operating lease liability-ST	7,544		7,362
Accrued product field action	547		2,096
Accrued sales taxes	3,205		2,615
Restructuring accrual	6,935		5,459
Deferred revenue	8,290		4,761
Accrued other taxes	1,154		4,054
Accrued professional fees	4,745		4,782
Legal accrual	970		826
Distribution fees	3,405		3,942
Warranties and returns	716		782
Accrued freight	12,623		11,238
Contract liabilities-ST	1,485		1,935
Contract settlement	1,250		1,667
Other	7,888		6,801
	$	120,009	$	117,776

Other long-term liabilities consist of the following (in thousands):



	March 31, 2020		December 31, 2019
Operating lease liability-LT	$	45,166	$	28,896
Benefits	1,148		1,131
Accrued rent	1,460		1,642
Contract liabilities-LT	438		472
Financing lease liability-LT	601		—
Deferred revenue	182		94
Other	1,046		585
	$	50,041	$	32,820

Income Taxes:	3 Months Ended
Income Taxes:	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Income Taxes Income taxes were accrued at an estimated effective tax rate of 17% and 7% for the three months ended March 31, 2020 and 2019, respectively. The effective tax rate for the three months ended March 31, 2020 differs from the federal statutory rate of 21% principally because of the effect of the mix of U.S. and foreign incomes, state income taxes, global intangible low-taxed income ("GILTI"), foreign-derived intangible income ("FDII") and tax credits. The effective tax rate for the three months ended March 31, 2019 differs from the federal statutory rate of 21% principally because of the effect of the mix of U.S. and foreign incomes, state income taxes, GILTI and tax credits. The effective tax rate during the three months ended March 31, 2019 included a discrete tax benefit of $5.6 million related to the excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the period. In addition, the effective tax rate during the three months ended March 31, 2019 included a discrete tax provision of $1.8 million as a result of a revaluation of the contingent consideration.

Long-Term Obligations (Notes)	3 Months Ended
Long-Term Obligations (Notes)	Mar. 31, 2020
LOng-Term Obligations Disclosure [Abstract]
Long-term Debt [Text Block]	Long-Term Obligations Five-year Senior Secured Revolving Credit Facility ("Credit Facility") On November 8, 2017, we entered into a Credit Facility with various lenders for $150.0 million, with Wells Fargo Bank, N.A. as the administrative agent, swingline lender and issuing lender. During March 2020, as a result of market uncertainty caused by the novel coronavirus ("COVID-19"), we preemptively borrowed $150.0 million on our Credit Facility as a conservative measure to manage any potential short-term liquidity risk. We plan to hold the proceeds of these borrowings as cash while the COVID-19 situation and market conditions remain uncertain. As of March 31, 2020, we had $150.0 million in borrowings and no availability under the Credit Facility. Principal payments on the revolving Credit Facility are made at our discretion with the unpaid amount due at maturity. The Credit Facility matures on November 8, 2022. Interest on borrowings under the Credit Facility, at our option, is based on the Base Rate plus applicable margin or the London Interbank Offered Rate ("LIBOR") plus applicable margin, see further details in Part II, Item 8, of our 2019 Annual Report on Form 10-K. Debt Covenants The Credit Facility contains certain financial covenants pertaining to Consolidated Fixed Charge Coverage and Consolidated Total Leverage Ratios. In addition, the Credit Facility has restrictions pertaining to limitations on debt, liens, negative pledges, loans, advances, acquisitions, other investments, dividends, distributions, redemptions, repurchases of equity interests, fundamental changes and asset sales and other dispositions, prepayments, redemptions and purchases of subordinated debt and other junior debt, transactions with affiliates, dividend and payment restrictions affecting subsidiaries, changes in line of business, fiscal year and accounting practices and amendment of organizational documents and junior debt documents. The Consolidated Leverage Ratio is defined as the ratio of Consolidated Total Funded Indebtedness on such date, to Consolidated Adjusted EBITDA, as defined under the Credit Facility Agreement, for the most recently completed four fiscal quarters. The maximum Consolidated Leverage Ratio is not more than 3.00 to 1.00. The Consolidated Fixed Charge Coverage Ratio is defined as the ratio of: (a) Consolidated Adjusted EBITDA less the sum of (i) capital expenditures, (ii) federal, state, local and foreign income taxes paid in cash and (iii) cash restricted payments made after the closing date, to (b) Consolidated Fixed Charges for the most recently completed four fiscal quarters, calculated on a pro forma basis. The minimum Consolidated Fixed Charge Coverage Ratio is 2.00 to 1.00. We were in compliance with all financial covenants as of March 31, 2020.

Stockholders' Equity (Notes)

3 Months Ended

Mar. 31, 2020

Stockholders' Equity Attributable to Parent [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Stockholders' Equity

Treasury Stock

In August 2019, our Board of Directors approved a new share purchase plan to purchase up to $100.0 million of our common stock. This plan replaced our existing plan and has no expiration date. During the three months ended March 31, 2020, we did not purchase any shares of our common stock under our stock purchase plans. As of March 31, 2020, all of the $100.0 million available for purchase was remaining under the plan. We are currently limited on share purchases in accordance with the terms and conditions of our Credit Facility (see Note 16: Long-Term Obligations).

For the three months ended March 31, 2020, we withheld 63,511 shares of our common stock from employee vested restricted stock units in consideration for $12.2 million in payments made on the employee's behalf for their minimum statutory income tax withholding obligations. For the three months ended March 31, 2019, we withheld 77,642 shares of our common stock from employee vested restricted stock units in consideration for $18.2 million in payments made on the employee's behalf for their minimum statutory income tax withholding obligations. Treasury stock is used to issue shares for stock option exercises, restricted stock grants and employee stock purchase plan stock purchases.

Accumulated Other Comprehensive (Loss) Income

The components of accumulated other comprehensive (loss) income ("AOCI"), net of tax, were as follows (in thousands):



	Foreign Currency Translation Adjustments			Unrealized Gains on Cash Flow Hedges			Other Adjustments			Total
Balance as of January 1, 2020	$	(17,310	)	$	1,880		$	28		$	(15,402	)
Other comprehensive loss before reclassifications	(10,477		)	(2,426		)	(81		)	(12,984		)
Amounts reclassified from AOCI	—			(526		)	—			(526		)
Other comprehensive loss	(10,477		)	(2,952		)	(81		)	(13,510		)
Balance as of March 31, 2020	$	(27,787	)	$	(1,072	)	$	(53	)	$	(28,912	)



	Foreign Currency Translation Adjustments			Unrealized Gains on Cash Flow Hedges			Other Adjustments		Total
Balance as of January 1, 2019	$	(17,682	)	$	638		$	99	$	(16,945	)
Other comprehensive (loss) income before reclassifications	(1,592		)	768			6		(818		)
Amounts reclassified from AOCI	—			(118		)	—		(118		)
Other comprehensive (loss) income	(1,592		)	650			6		(936		)
Balance as of March 31, 2019	$	(19,274	)	$	1,288		$	105	$	(17,881	)

Commitments and Contingencies:	3 Months Ended
Commitments and Contingencies:	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies [Text Block]	Commitments and Contingencies Legal Proceedings Beginning in November 2016, purported class actions were filed in the U.S. District Court for the Northern District of Illinois against Pfizer, Inc. subsidiaries, Hospira, Inc., Hospira Worldwide, Inc. and certain other defendants relating to the intravenous saline solutions part of the HIS business. Plaintiffs seek to represent classes consisting of all persons and entities in the U.S. who directly purchased intravenous saline solution sold by any of the defendants from January 1, 2013 until the time the defendants’ allegedly unlawful conduct ceases. Plaintiffs allege that U.S. manufacturer defendants conspired together to restrict output and artificially fix, raise, maintain and/or stabilize the prices of intravenous saline solution sold throughout the U.S. in violation of federal antitrust laws. Plaintiffs seek treble damages (for themselves and on behalf of the putative classes) and an injunction against defendants for alleged price overcharges for intravenous saline solution in the U.S. since January 1, 2013. On July 5, 2018, the District Court granted defendants’ motion to dismiss the operative complaint for failing to state a valid antitrust claim, but allowed the plaintiffs to file a second amended complaint. On September 6, 2018, plaintiffs filed a second amended complaint adding new allegations in support of their conspiracy claims and adding ICU as a defendant. All defendants filed a motion to dismiss this second amended complaint and on April 3, 2020, the District Court granted Defendants’ motion to dismiss the second amended complaint. The District Court concluded that it would be futile to permit plaintiffs to amend their complaint again, and dismissed the case with prejudice. The plaintiffs may file an appeal or other type of challenge to the District Court’s order. On February 3, 2017, we completed the acquisition of the HIS business from Pfizer. This litigation is the subject of a claim for indemnification against us by Pfizer and a cross-claim for indemnification against Pfizer by us under the HIS stock and asset purchase agreement. From time to time, we are involved in various legal proceedings, most of which are routine litigation, in the normal course of business. Our management does not believe that the resolution of the unsettled legal proceedings that we are involved with will have a material adverse impact on our financial position or results of operations. Off-Balance Sheet Arrangements In the normal course of business, we have agreed to indemnify our officers and directors to the maximum extent permitted under Delaware law and to indemnify customers as to certain intellectual property matters or other matters related to sales of our products. There is no maximum limit on the indemnification that may be required under these agreements. Although we can provide no assurances, we have never incurred, nor do we expect to incur, any material liability for indemnification. Contingencies During November 2019, we acquired Pursuit. Total consideration for the acquisition includes a potential contractual earn-out of up to $50.0 million, to be paid to former Pursuit equity holders, calculated based upon the achievement of certain performance targets during the earn-out period (see Note 8: Fair Value Measurement). Commitments We have non-cancellable operating lease agreements where we are contractually obligated to pay certain lease payment amounts (see Note 5: Leases).

Collaborative and Other Arrangements (Notes)	3 Months Ended
Collaborative and Other Arrangements (Notes)	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangement Disclosure [Text Block]	Collaborative and Other Arrangements On February 3, 2017, we entered into two Manufacturing and Supply Agreements ("MSAs"), (i) whereby Pfizer will manufacture and supply us with certain agreed upon products for an initial five-year term with a one-time two-year option to extend and (ii) whereby we will manufacture and supply Pfizer certain agreed upon products for a term of five or ten years depending on the product, also with a one-time two-year option to extend. The MSAs provide each party with mutually beneficial interests and both of the MSAs are to be jointly managed by both Pfizer and ICU. The initial supply price, which will be annually updated, is in full consideration for all costs associated with the manufacture, documentation, packaging and certification of the products.

Subsequent Events (Notes)	3 Months Ended
Subsequent Events (Notes)	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Subsequent Events In late 2019, a novel coronavirus (“COVID-19”) was first reported in Wuhan, China, and on March 11, 2020, the World Health Organization characterized COVID-19 as a global pandemic. The spread of COVID-19 around the world in 2020 has caused significant volatility in U.S. and international markets. The ultimate disruption caused by the outbreak is uncertain; however, it may result in a material adverse impact on our financial position, results of operations and cash flows. Possible impact may include, but is not limited to: lost revenue or additional costs associated with a disruption to our production or distribution facilities; customers may experience financial difficulties and may be unable to pay within payment terms for the products they purchased; reduced revenue due to restricted access to healthcare customers; lower revenue and income due to foreign currency fluctuations; lower travel and entertainment costs due to travel restrictions; and lower income due to a delay in cost savings projects. While our operations have been designated as essential activities by certain state and city jurisdictions, COVID-19 is likely to negatively impact our operating results and financial position, the extent and duration cannot be reasonably estimated at this time.

Restructuring, Strategic Transaction and Integration (Tables)

3 Months Ended

Mar. 31, 2020

Restructuring, Strategic Transaction and Integration [Abstract]

Restructuring and Related Costs [Table Text Block]

The following table summarizes the details of changes in our restructuring-related accrual for the period ended March 31, 2020 (in thousands):



	Accrued Balance January 1, 2020		Charges Incurred		Payments			Accrued Balance March 31, 2020
Severance pay and benefits	$	3,878	$	3,111	$	(2,620	)	$	4,369
Employment agreement buyout	460		—		(186		)	274
Facility closure expenses	1,211		4,062		(3,501		)	1,772
	$	5,549	$	7,173	$	(6,307	)	$	6,415

Revenue (Tables)

3 Months Ended

Mar. 31, 2020

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue [Table Text Block]

The following table represents our revenues disaggregated by geography (in thousands):



	For the three months ended March 31,
Geography	2020		2019
Europe, the Middle East and Africa	$	37,928	$	32,378
Other Foreign	60,521		51,361
Total Foreign	98,449		83,739
United States	230,158		247,193
Total Revenues	$	328,607	$	330,932

The following table represents our revenues disaggregated by product (in thousands):



	For the three months ended March 31,
Product line	2020		2019
Infusion Consumables	$	123,507	$	120,580
Infusion Systems	88,380		84,282
IV Solutions	104,291		113,182
Critical Care	12,429		12,888
Total Revenues	$	328,607	$	330,932

Contract with Customer, Asset and Liability [Table Text Block]

The following table presents our changes in the contract balances for the three months ended March 31, 2020 and 2019 (in thousands):



	Contract Liabilities
Beginning balance, January 1, 2020	$	(4,855	)
Equipment revenue recognized	1,802
Equipment revenue deferred due to implementation	(3,990		)
Software revenue recognized	1,235
Software revenue deferred due to implementation	(2,664		)
Ending balance, March 31, 2020	$	(8,472	)

Beginning balance, January 1, 2019	$	(4,282	)
Equipment revenue recognized	448
Equipment revenue deferred due to implementation	(1,343		)
Software revenue recognized	345
Software revenue deferred due to implementation	(1,593		)
Ending balance, March 31, 2019	$	(6,425	)

Leases (Tables)

3 Months Ended

Mar. 31, 2020

Lease, Cost [Table Text Block]

The following table presents the components of our lease cost (in thousands):



	For the three months ended March 31,
	2020		2019
Operating lease cost	$	2,791	$	2,430

Finance lease cost	29		—

Short-term lease cost	54		96

Total lease cost	$	2,874	$	2,526

Leases Supplemental Cash Flow (Tables)

3 Months Ended

Mar. 31, 2020

Cash Flow, Supplemental Disclosures [Text Block]

The following table presents the supplemental cash flow information related to our leases (in thousands):



	For the three months ended March 31,
	2020		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	2,457	$	2,219
Operating cash flows from finance leases	$	29	$	—

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	19,094	$	98
Finance leases	$	800	$	—

Leases Supplemental Balance Sheet (Tables)

3 Months Ended

Mar. 31, 2020

Assets and Liabilities, Leases [Table Text Block]

The following table presents the supplemental balance sheet information related to our operating leases (in thousands, except lease term and discount rate):



	As of March 31, 2020			As of December 31, 2019
Operating leases
Operating lease right-of-use assets	$	50,430		$	34,465

Accrued liabilities	$	7,544		$	7,362
Other long-term liabilities	45,166			28,896
Total operating lease liabilities	$	52,710		$	36,258

Weighted Average Remaining Lease Term
Operating leases	7.3 years			6.0 years

Weighted Average Discount Rate
Operating leases	5.06		%	5.57		%

Leases Maturity (Tables)

3 Months Ended

Mar. 31, 2020

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

As of March 31, 2020, the maturities of our operating and financing lease liabilities for each of the next five years is approximately (in thousands):



	Operating Leases			Finance Leases
Remainder of 2020	$	7,195		$	174
2021	10,021			218
2022	9,309			218
2023	8,494			218
2024	8,094			25
2025	4,816			—
Thereafter	14,906			—
Total Lease Payments	62,835			853
Less imputed interest	(10,125		)	(64		)
Total	$	52,710		$	789

Net Income Per Share (Tables)

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands, except per share data):



	Three months ended March 31,
	2020		2019
Net income	$	16,834	$	30,998
Weighted-average number of common shares outstanding (for basic calculation)	20,780		20,527
Dilutive securities	727		1,024
Weighted-average common and common equivalent shares outstanding (for diluted calculation)	21,507		21,551
EPS — basic	$	0.81	$	1.51
EPS — diluted	$	0.78	$	1.44

Derivative Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]

The following table presents the fair values of our derivative instruments included within the Condensed Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019 (in thousands):



	Derivatives
	Condensed Consolidated Balance Sheet Location	March 31, 2020			December 31, 2019
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contract:
	Prepaid expenses and other current assets	$	—		$	2,366
	Accrued liabilities	(1,006		)	—
	Other long-term liabilities	(512		)	—
Total derivatives designated as cash flow hedging instruments		$	(1,518	)	$	2,366

The following table presents the amounts affecting the Condensed Consolidated Statements of Operations for the three months ended March 31, 2020 and 2019 (in thousands):



	Line Item in the Condensed Consolidated Statements of Operations	Three months ended March 31,
		2020		2019
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contracts	Cost of goods sold	$	692	$	155

Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]

We recognized the following (losses) gains on our foreign exchange contracts designated as a cash flow hedge (in thousands):



	Amount of (Loss) Gain Recognized in Other Comprehensive Income on Derivatives					Amount of Gain Reclassified From Accumulated Other Comprehensive Income into Income
	Three months ended March 31,						Three months ended March 31,
	Three months ended March 31,						Three months ended March 31,
	2020			2019		Location of Gain Reclassified From Accumulated Other Comprehensive Income into Income	2020		2019
Derivatives designated as cash flow hedges:
Foreign exchange forward contract	$	(3,192	)	$	1,010	Cost of goods sold	$	692	$	155
Total derivatives designated as cash flow hedging instruments	$	(3,192	)	$	1,010		$	692	$	155

Fair Value Measurement (Tables)

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following tables provide a reconciliation of the Level 3 earn-out liabilities measured at estimated fair value (in thousands):



	Pursuit
	Earn-out Liability
Accrued balance, January 1, 2020	$	17,300
Change in fair value of earn-out (included in income from operations as a separate line item)	—
Accrued balance, March 31, 2020	$	17,300

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

The following tables provide quantitative information about Level 3 inputs for fair value measurement of our earn-out liabilities:

Pursuit Earn-out



Simulation Input	As of March 31, 2020		At Acquisition November 2, 2019
Revenue/Gross Profit Volatility	20.00	%	20.00	%
Discount Rate	15.00	%	15.00	%
Risk Free Rate	1.55	%	1.55	%
Counter Party Risk	6.00	%	6.00	%

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

Our assets and liabilities measured at fair value on a recurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):



	Fair value measurements at March 31, 2020
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Available for sale securities:
Short-term	$	20,115	$	—	$	20,115	$	—
Total Assets	$	20,115	$	—	$	20,115	$	—

Liabilities:
Earn-out liability	$	17,300	$	—	$	—	$	17,300
Foreign exchange forwards:
Accrued liabilities	1,006		—		1,006		—
Other long-term liabilities	512		—		512		—
Total Liabilities	$	18,818	$	—	$	1,518	$	17,300



	Fair value measurements at December 31, 2019
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Available for sale securities:
Short-term	$	23,967	$	—	$	23,967	$	—
Foreign exchange forwards:
Prepaid expenses and other current assets	2,366		—		2,366		—
Total Assets	$	26,333	$	—	$	26,333	$	—

Liabilities:
Earn-out liability	$	17,300	$	—	$	—	$	17,300
Total Liabilities	$	17,300	$	—	$	—	$	17,300

Investment Securities (Tables)

3 Months Ended

Mar. 31, 2020

Investments, Debt and Equity Securities [Abstract]

Available-for-sale Securities [Table Text Block]

Our short investment securities consisted of the following (in thousands):



	As of March 31, 2020
	Amortized Cost		Unrealized Holding Gains (Losses)		Fair Value
Short-term corporate bonds	$	20,115	$	—	$	20,115

	As of December 31, 2019
	Amortized Cost		Unrealized Holding Gains (Losses)		Fair Value
Short-term corporate bonds	$	23,967	$	—	$	23,967

Prepaids and Other Current Assets (Tables)

3 Months Ended

Mar. 31, 2020

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

Prepaid expenses and other current assets consist of the following (in thousands):



	March 31, 2020		December 31, 2019
Other prepaid expenses and receivables	15,407		13,778
Deferred costs	6,493		3,332
Prepaid insurance and property taxes	4,548		5,450
VAT/GST receivable	3,913		4,422
Deferred tax charge	1,266		1,266
Deposits	1,316		1,375
Other	1,658		4,358
	$	34,601	$	33,981

Inventories (Tables)

3 Months Ended

Mar. 31, 2020

Inventory Disclosure [Abstract]

Schedule of Inventory, Current [Table Text Block]

Inventories consisted of the following (in thousands):



	March 31, 2020		December 31, 2019
Raw materials	$	121,674	$	119,709
Work in process	36,291		39,515
Finished goods	153,639		178,416
Total inventories	$	311,604	$	337,640

Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2020

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment consisted of the following (in thousands):



	March 31, 2020			December 31, 2019
Machinery and equipment	$	241,059		$	219,057
Land, building and building improvements	233,548			230,454
Molds	60,312			60,155
Computer equipment and software	93,475			83,217
Furniture and fixtures	7,416			7,498
Instruments placed with customers⁽¹⁾	74,292			74,434
Construction in progress	77,483			101,425
Total property and equipment, cost	787,585			776,240
Accumulated depreciation	(331,961		)	(320,155		)
Property and equipment, net	$	455,624		$	456,085

Goodwill and Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill [Table Text Block]

The following table presents the changes in the carrying amount of our goodwill (in thousands):



	Total
Balance as of January 1, 2020	$	31,245
Currency translation	(478		)
Balance as of March 31, 2020	$	30,767

Schedule of Intangible Assets and Goodwill [Table Text Block]

Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):



	Weighted Average	March 31, 2020
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	22,854	$	13,886	$	8,968
Customer contracts	12	10,093		5,584		4,509
Non-contractual customer relationships	9	56,258		21,102		35,156
Trademarks	4	425		425		—
Trade name	15	18,237		2,555		15,682
Developed technology	13	152,893		27,403		125,490
Non-compete	3	2,500		347		2,153
Total amortized intangible assets		$	263,260	$	71,302	$	191,958

Internally developed software*		$	14,879			$	14,879

Total intangible assets		$	278,139	$	71,302	$	206,837

______________________________

* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.



	Weighted Average	December 31, 2019
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	22,322	$	13,519	$	8,803
Customer contracts	12	10,122		5,506		4,616
Non-contractual customer relationships	9	57,296		19,787		37,509
Trademarks	4	425		425		—
Trade name	15	18,256		2,254		16,002
Developed technology	13	152,354		24,228		128,126
Non-compete	3	2,500		139		2,361

Total amortized intangible assets		$	263,275	$	65,858	$	197,417

Internally developed software*		$	13,991			$	13,991

Total intangible assets		$	277,266	$	65,858	$	211,408

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

As of March 31, 2020 estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands):



Remainder of 2020	$	17,424
2021	22,997
2022	22,355
2023	21,512
2024	21,422
2025	15,629
Thereafter	70,619
Total	$	191,958

Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2020

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities consist of the following (in thousands):



	March 31, 2020		December 31, 2019
Salaries and benefits	$	27,616	$	21,116
Incentive compensation	8,638		15,221
Accrued supply chain restructuring costs	22,998		23,119
Operating lease liability-ST	7,544		7,362
Accrued product field action	547		2,096
Accrued sales taxes	3,205		2,615
Restructuring accrual	6,935		5,459
Deferred revenue	8,290		4,761
Accrued other taxes	1,154		4,054
Accrued professional fees	4,745		4,782
Legal accrual	970		826
Distribution fees	3,405		3,942
Warranties and returns	716		782
Accrued freight	12,623		11,238
Contract liabilities-ST	1,485		1,935
Contract settlement	1,250		1,667
Other	7,888		6,801
	$	120,009	$	117,776

Other long-term liabilities consist of the following (in thousands):



	March 31, 2020		December 31, 2019
Operating lease liability-LT	$	45,166	$	28,896
Benefits	1,148		1,131
Accrued rent	1,460		1,642
Contract liabilities-LT	438		472
Financing lease liability-LT	601		—
Deferred revenue	182		94
Other	1,046		585
	$	50,041	$	32,820

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2020

Stockholders' Equity Attributable to Parent [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

The components of accumulated other comprehensive (loss) income ("AOCI"), net of tax, were as follows (in thousands):



	Foreign Currency Translation Adjustments			Unrealized Gains on Cash Flow Hedges			Other Adjustments			Total
Balance as of January 1, 2020	$	(17,310	)	$	1,880		$	28		$	(15,402	)
Other comprehensive loss before reclassifications	(10,477		)	(2,426		)	(81		)	(12,984		)
Amounts reclassified from AOCI	—			(526		)	—			(526		)
Other comprehensive loss	(10,477		)	(2,952		)	(81		)	(13,510		)
Balance as of March 31, 2020	$	(27,787	)	$	(1,072	)	$	(53	)	$	(28,912	)



	Foreign Currency Translation Adjustments			Unrealized Gains on Cash Flow Hedges			Other Adjustments		Total
Balance as of January 1, 2019	$	(17,682	)	$	638		$	99	$	(16,945	)
Other comprehensive (loss) income before reclassifications	(1,592		)	768			6		(818		)
Amounts reclassified from AOCI	—			(118		)	—		(118		)
Other comprehensive (loss) income	(1,592		)	650			6		(936		)
Balance as of March 31, 2019	$	(19,274	)	$	1,288		$	105	$	(17,881	)

Restructuring, Strategic Transaction and Integration Restructuring, Strategic Transaction and Integration (Details) - USD ($)
$ in Millions

3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Restructuring and Related Activities [Abstract]

Restructuring, Impairment, and Other Activities Disclosure [Text Block]

Restructuring, Strategic Transaction and Integration

Restructuring, strategic transaction and integration expenses were $12.3 million and $24.4 million for the three months ended March 31, 2020 and 2019, respectively.

Restructuring

During the three months ended March 31, 2020 and 2019, restructuring charges were $7.2 million and $0.8 million, respectively. Restructuring charges for the three months ended March 31, 2020, were primarily related to severance and costs related to office and other facility closures.

During the year ended December 31, 2015, we incurred restructuring charges related to an agreement with Dr. Lopez, a member of our Board of Directors and a former employee in our research and development department, pursuant to which we bought out Dr. Lopez's right to employment under his then-existing employment agreement. The buy-out, including payroll taxes, is paid in equal monthly installments until December 2020.

The following table summarizes the details of changes in our restructuring-related accrual for the period ended March 31, 2020 (in thousands):



	Accrued Balance January 1, 2020		Charges Incurred		Payments			Accrued Balance March 31, 2020
Severance pay and benefits	$	3,878	$	3,111	$	(2,620	)	$	4,369
Employment agreement buyout	460		—		(186		)	274
Facility closure expenses	1,211		4,062		(3,501		)	1,772
	$	5,549	$	7,173	$	(6,307	)	$	6,415

Strategic transaction and integration expenses

We incurred and expensed $5.1 million and $23.6 million in strategic transaction and integration expenses during the three months ended March 31, 2020 and 2019, respectively. The strategic transaction and integration expenses during the three months ended March 31, 2020 and 2019, were primarily related to the integration of the Hospira Infusion Systems ("HIS") business acquired in 2017 from Pfizer. For the three months ended March 31, 2020, the expenses included the migration of IT systems at our Austin facility. The strategic transaction and integration expenses during the three months ended March 31, 2019, were primarily related to our final Pfizer separation costs and clean-up, which included a $12.7 million non-cash write-off of related assets.

Restructuring, strategic transaction and integration

$ 12.3

$ 24.4

Restructuring Costs

$ 7.2

$ 0.8

Restructuring, Strategic Transaction and Integration (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 5,549
Restructuring Charges	7,173
Payments for Restructuring	6,307
Restructuring Reserve	6,415
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	3,878
Restructuring Charges	3,111
Payments for Restructuring	2,620
Restructuring Reserve	4,369
Special Termination Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	460
Restructuring Charges	0
Payments for Restructuring	186
Restructuring Reserve	274
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	1,211
Restructuring Charges	4,062
Payments for Restructuring	3,501
Restructuring Reserve	$ 1,772

Restructuring, Strategic Transaction and Integration Strategic Transaction and Integration (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Restructuring and Related Activities [Abstract]
Strategic Transaction and Integration	$ 5.1	$ 23.6
Cleanupcosts		$ 12.7

Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
Revenue (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 328,607	$ 330,932
Infusion Systems [Member]
Disaggregation of Revenue [Line Items]
Revenues	88,380	$ 84,282
Equipment revenue [Member]
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Amount	6,800
Software revenue [Member]
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 1,600

Revenue Disaggregated Revenue by Geography (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 328,607	$ 330,932
EMEA [Member]
Disaggregation of Revenue [Line Items]
Revenues	37,928	32,378
Other foreign countries [Member]
Disaggregation of Revenue [Line Items]
Revenues	60,521	51,361
Foreign [Member]
Disaggregation of Revenue [Line Items]
Revenues	98,449	83,739
UNITED STATES
Disaggregation of Revenue [Line Items]
Revenues	$ 230,158	$ 247,193

Revenue Disaggregated Revenue by Product Line (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 328,607	$ 330,932
Infusion Consumables [Member]
Disaggregation of Revenue [Line Items]
Revenues	123,507	120,580
IV Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenues	104,291	113,182
Infusion Systems [Member]
Disaggregation of Revenue [Line Items]
Revenues	88,380	84,282
Critical Care [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 12,429	$ 12,888

Revenue Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Movement in Deferred Revenue [Roll Forward]
Contract with Customer, Liability	$ (4,855)	$ (4,282)
Contract with Customer, Liability	(8,472)	(6,425)
Equipment revenue [Member]
Movement in Deferred Revenue [Roll Forward]
Deferred Revenue, Additions	(3,990)	(1,343)
Increase (Decrease) in Deferred Revenue	1,802	448
Software revenue [Member]
Movement in Deferred Revenue [Roll Forward]
Deferred Revenue, Additions	(2,664)	(1,593)
Increase (Decrease) in Deferred Revenue	$ 1,235	$ 345

Leases (Details) - USD ($) $ in Thousands	3 Months Ended
Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating Lease, Cost	$ 2,791	$ 2,430
Finance Lease, Right-of-Use Asset, Amortization	29	0
Short-term Lease, Cost	54	96
Lease, Cost	$ 2,874	$ 2,526

Leases Cash Flow, Operating Activities, Lessee (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating Lease, Payments	$ 2,457	$ 2,219
Finance Lease, Interest Payment on Liability	29	0
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	19,094	98
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	$ 800	$ 0

Leases Assets and Liabilities, Lessee (Details) - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Mar. 31, 2019

Finance Lease, Right-of-Use Asset

$ 789

Operating Lease, Right-of-Use Asset

50,430

$ 34,465

^[1]

$ 34,465

Operating Lease, Liability, Current

7,544

7,362

Operating Lease, Liability, Noncurrent

45,166

28,896

Operating Lease, Liability

$ 52,710

$ 36,258

Operating Lease, Weighted Average Remaining Lease Term

7 years 3 months 18 days

6 years

Operating Lease, Weighted Average Discount Rate, Percent

5.06%

5.57%

Finance Lease, Liability, Current

$ 188

Finance Lease, Liability, Noncurrent

601

$ 0

Finance Lease, Liability

$ 789

Finance Lease, Weighted Average Remaining Lease Term

4 years

Finance Lease, Weighted Average Discount Rate, Percent

4.32%

[1]	December 31, 2019 balances were derived from audited consolidated financial statements.

Leases Maturity (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Finance Lease, Liability, Payments, Due Year Five	$ 0
Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months	10,021
Finance Lease, Liability, Payments, Due Next Twelve Months	218
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	7,195
Finance Lease, Liability, Payments, Remainder of Fiscal Year	174
Lessee, Operating Lease, Liability, Payments, Due Year Two	9,309
Finance Lease, Liability, Payments, Due Year Two	218
Lessee, Operating Lease, Liability, Payments, Due Year Four	8,494
Finance Lease, Liability, Payments, Due Year Three	218
Lessee, Operating Lease, Liability, Payments, Due Year Five	8,094
Lessee, Operating Lease, Liability, Payments, Due Year Five	4,816
Lessee, Operating Lease, Liability, Payments, Due after Year Five	14,906
Finance Lease, Liability, Payments, Due after Year Five	0
Lessee, Operating Lease, Liability, Payments, Due	62,835
Finance Lease, Liability, Payment, Due	853
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(10,125)
Finance Lease, Liability, Undiscounted Excess Amount	(64)
Operating Lease, Liability	52,710	$ 36,258
Finance Lease, Liability, Payments, Due Year Four	25
Finance Lease, Liability	$ 789

Leases Text (Details)	3 Months Ended
Leases Text (Details)	Mar. 31, 2020
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Option to Extend	5 years
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	15 years

Net Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	15,333	9,998
Net Income	$ 16,834	$ 30,998
Weighted average number of common shares outstanding (for basic calculation)	20,780,000	20,527,000
Dilutive securities	727,000	1,024,000
Diluted (in shares)	21,507,000	21,551,000
EPS - basic	$ 0.81	$ 1.51
Diluted (In dollars per share)	$ 0.78	$ 1.44

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

CONTINGENT EARN-OUT LIABILITY

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686

+ Details

Net Income Per Share (Details 1) - shares	3 Months Ended
Net Income Per Share (Details 1) - shares	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	15,333	9,998

Derivative Financial Instruments (Details) $ in Millions, $ in Millions	Mar. 31, 2020 USD ($)	Mar. 31, 2020 MXN ($)
Derivative [Line Items]
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	$ 1.0
Hedge 2 [Member]
Derivative [Line Items]
Derivative, Forward Exchange Rate	24.26	24.26
Derivative Asset, Notional Amount		$ 473.2
Hedge 3 [Member] [Member]
Derivative [Line Items]
Derivative, Forward Exchange Rate	22.109	22.109
Derivative Asset, Notional Amount		$ 265.3

Derivative Financial Instruments Derivative Instruments and Hedging Activities - FV of Derivative Instruments Included Within Consolidated Balance Sheet (Details) - Foreign Exchange Forward [Member] - Designated as Hedging Instrument [Member] - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Prepaid Expenses and Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset	$ 0	$ (2,366)
Derivative Financial Instruments, Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset	(1,518)
Derivative Financial Instruments, Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability		(2,366)
Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability	(1,006)	0
Other Noncurrent Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability	$ (512)	$ 0

Derivative Financial Instruments Derivative Instruments and Hedging Activities - Amounts Affecting Consolidated Statements of Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	$ 692	$ 155

Derivative Financial Instruments Derivative Instruments and Hedging Activities - Cash Flow Hedge Activity Included in Accumulated Other Comprehensive Income (Loss) (Details) - Cost of Sales [Member] - Foreign Exchange Forward [Member] - Cash Flow Hedging [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Instruments, Gain Recognized in Other Comprehensive Income (Loss), Effective Portion	$ (3,192)	$ 1,010
Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion	$ 692	$ 155

Fair Value Measurement Fair Value Measurement (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Hospira [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
contingent consideration gross		$ 225.0
Pursuit Vascular, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
contingent consideration gross	$ 50.0	$ 50.0

Fair Value Measurement Fair Value Liabilities Measured on Recurring Basis, Unobservable Inputs (Details) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2019

^[1]

Dec. 31, 2018

Fair Value Disclosures [Abstract]

$ 17,300

$ 39,700

$ 17,300

$ 47,400

Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)

$ 0

$ 7,700

[1]	December 31, 2019 balances were derived from audited consolidated financial statements.

Fair Value Measurement Fair Value Inputs, Liabilities, Quantitative Information Pursuit (Details)	Mar. 31, 2020	Dec. 31, 2019
MeasurementinputadjustedEBITDAvolatility [Domain]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.2000	0.2000
Measurement Input, Discount Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.1500	0.1500
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.0155	0.0155
Measurement Input, Market Price of Risk [Domain]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.0600	0.0600

Fair Value Measurement Fair Value Inputs, Liabilities, Quantitative Information Hospira (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2019	Mar. 31, 2020
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input		0.0155	0.0155
Hospira [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Assumptions, Expected Volatility Rate-Adjusted EBITDA	30.00%	30.00%
Fair Value Assumptions, Market Price of Risk	5.47%	5.24%
Fair Value Assumptions, Cost of Debt	4.35%	5.25%
Hospira [Member] \| Measurement Input, Cost of Debt [Domain]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.0825	0.0825
Hospira [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.0263	0.0287

Fair Value Measurement Fair Value Measurements, Recurring Basis (Details) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2019

Dec. 31, 2018

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

CONTINGENT EARN-OUT LIABILITY

$ 17,300

$ 39,700

$ 17,300

^[1]

$ 47,400

20,115

23,967

^[1]

26,333

Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)

20,115

$ (7,700)

Prepaid Expenses and Other Current Assets [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign Currency Contract, Asset, Fair Value Disclosure

2,366

Accrued Liabilities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign Currency Contracts, Liability, Fair Value Disclosure

1,006

Other Noncurrent Liabilities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign Currency Contracts, Liability, Fair Value Disclosure

512

Fair Value, Inputs, Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value, Inputs, Level 1 [Member] | Prepaid Expenses and Other Current Assets [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign Currency Contract, Asset, Fair Value Disclosure

Fair Value, Inputs, Level 1 [Member] | Accrued Liabilities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign Currency Contracts, Liability, Fair Value Disclosure

Fair Value, Inputs, Level 1 [Member] | Other Noncurrent Liabilities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign Currency Contracts, Liability, Fair Value Disclosure

Fair Value, Inputs, Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

20,115

23,967

26,333

Fair Value, Inputs, Level 2 [Member] | Prepaid Expenses and Other Current Assets [Member]

20,115

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign Currency Contract, Asset, Fair Value Disclosure

2,366

Fair Value, Inputs, Level 2 [Member] | Accrued Liabilities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign Currency Contracts, Liability, Fair Value Disclosure

1,006

Fair Value, Inputs, Level 2 [Member] | Other Noncurrent Liabilities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign Currency Contracts, Liability, Fair Value Disclosure

512

Fair Value, Inputs, Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value, Inputs, Level 3 [Member] | Prepaid Expenses and Other Current Assets [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign Currency Contract, Asset, Fair Value Disclosure

Fair Value, Inputs, Level 3 [Member] | Accrued Liabilities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign Currency Contracts, Liability, Fair Value Disclosure

Fair Value, Inputs, Level 3 [Member] | Other Noncurrent Liabilities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign Currency Contracts, Liability, Fair Value Disclosure

Earn-out liability [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Earn-out liability [Member] | Fair Value, Inputs, Level 1 [Member]

17,300

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Earn-out liability [Member] | Fair Value, Inputs, Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Earn-out liability [Member] | Fair Value, Inputs, Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Liabilities, Total [Member]

17,300

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Liabilities, Total [Member] | Fair Value, Inputs, Level 1 [Member]

18,818

17,300

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Liabilities, Total [Member] | Fair Value, Inputs, Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Liabilities, Total [Member] | Fair Value, Inputs, Level 3 [Member]

1,518

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Prepaid Expense and Other Assets, Current [Abstract]

$ 17,300

[1]	December 31, 2019 balances were derived from audited consolidated financial statements.

Investment Securities (Details) $ in Thousands	3 Months Ended
Investment Securities (Details) $ in Thousands	Mar. 31, 2020 USD ($)
Debt Securities, Available-for-sale [Line Items]
Gain (Loss) on Sale of Investments	$ 0

Investment Securities Table (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Current	$ 20,115	$ 23,967
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value	20,115	23,967
Available-for-sale Debt Security Current [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	$ 0	$ 0

Prepaids and Other Current Assets Prepaids and Other Assets (Details) - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Deposit Assets

$ 1,316

$ 1,375

Other Prepaid Expense, Current

15,407

13,778

Deferred Costs and Other Assets

6,493

3,332

Prepaid insurance and property taxes

4,548

5,450

Prepaid Taxes

3,913

4,422

Deferred tax charge

1,266

Other Assets, Current

1,658

4,358

Prepaid expenses and other current assets

$ 34,601

$ 33,981

^[1]

[1]	December 31, 2019 balances were derived from audited consolidated financial statements.

Inventories (Details) - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Inventory Disclosure [Abstract]

Inventory, Raw Materials, Net of Reserves

$ 121,674

$ 119,709

Inventory, Work in Process, Net of Reserves

36,291

39,515

Inventory, Finished Goods, Net of Reserves

153,639

178,416

Total

$ 311,604

$ 337,640

^[1]

[1]	December 31, 2019 balances were derived from audited consolidated financial statements.

Property and Equipment (Details) - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Net property and equipment

$ 787,585

$ 776,240

Accumulated depreciation

(331,961)

(320,155)

455,624

456,085

^[1]

Machinery and Equipment, Gross

241,059

219,057

Furniture and Fixtures, Gross

7,416

7,498

Construction in Progress, Gross

77,483

101,425

Land, Buildings and Improvements [Member]

233,548

230,454

Molds [Member]

Computer Equipment and Software [Member]

60,312

60,155

Instruments Placed with Customers [Member]

93,475

83,217

Goodwill, Foreign Currency Translation Gain (Loss)

$ 74,292

$ 74,434

[1]	December 31, 2019 balances were derived from audited consolidated financial statements.

Property and Equipment Text (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation	$ 15.2	$ 15.1

Goodwill and Intangible Assets Goodwill Table (Details)
$ in Thousands

3 Months Ended

Mar. 31, 2020

USD ($)

Goodwill [Line Items]

GOODWILL

$ 31,245

^[1]

(478)

GOODWILL

$ 30,767

[1]	December 31, 2019 balances were derived from audited consolidated financial statements.

Goodwill and Intangible Assets Intangibles Table (Details) - USD ($)
$ in Thousands

3 Months Ended

12 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Finite-Lived Intangible Assets, Accumulated Amortization

$ 263,260

$ 263,275

71,302

65,858

Indefinite-lived Intangible Assets (Excluding Goodwill)

191,958

197,417

14,879

13,991

Intangible Assets, Gross (Excluding Goodwill)

278,139

277,266

INTANGIBLE ASSETS, net

$ 206,837

$ 211,408

^[1]

Patents [Member]

10 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 22,854

$ 22,322

13,886

13,519

Customer Contracts [Member]

$ 8,968

$ 8,803

12 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 10,093

$ 10,122

5,584

5,506

$ 4,509

$ 4,616

9 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 56,258

$ 57,296

21,102

19,787

$ 35,156

$ 37,509

Trademarks [Member]

4 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 425

425

$ 0

Trade Names [Member]

15 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 18,237

$ 18,256

2,555

2,254

Developed Technology Rights [Member]

$ 15,682

$ 16,002

13 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 152,893

$ 152,354

27,403

24,228

Noncompete Agreements [Member]

$ 125,490

$ 128,126

3 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 2,500

347

139